[1] |
World Health Organization. Schistosomiasis: key facts[EB/OL]. (2021-11-18)[2021-12-10]. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis.
|
[2] |
McManus DP, Dunne DW, Sacko M, et al. Schistosomiasis[J]. Nat Rev Dis Primers, 2018, 4(1): 13.
doi: 10.1038/s41572-018-0013-8
pmid: 30093684
|
[3] |
Colley DG, Andros TS, Campbell CH Jr. Schistosomiasis is more prevalent than previously thought: what does it mean for public health goals, policies, strategies, guidelines and intervention programs?[J]. Infect Dis Poverty, 2017, 6: 63.
doi: 10.1186/s40249-017-0275-5
|
[4] |
Liang YS. Studies on resistance of Schistosoma to praziquantel in China[J]. Chin Trop Med, 2019, 19(7): 603-607. (in Chinese)
|
|
( 梁幼生. 我国血吸虫对吡喹酮抗药性研究之概要[J]. 中国热带医学, 2019, 19(7): 603-607.)
|
[5] |
Cohen J. Unfilled vials[J]. Science, 2016, 351(6268): 16-19.
doi: 10.1126/science.351.6268.16
pmid: 26721985
|
[6] |
Stylianou A, Hadjichrysanthou C, Truscott JE, et al. Developing a mathematical model for the evaluation of the potential impact of a partially efficacious vaccine on the transmission dynamics of Schistosoma mansoni in human communities[J]. Parasit Vectors, 2017, 10(1): 294.
doi: 10.1186/s13071-017-2227-0
pmid: 28623957
|
[7] |
Colley DG, Secor WE. Immunology of human schistosomiasis[J]. Parasite Immunol, 2014, 36(8): 347-357.
doi: 10.1111/pim.12087
pmid: 25142505
|
[8] |
Fonseca CT, Oliveira SC, Alves CC. Eliminating schistosomes through vaccination: what are the best immune weapons?[J]. Front Immunol, 2015, 6: 95.
|
[9] |
Wang SP, Chen XC, Gao DM. Research progress on schistosome vaccine and prospect of its application in China[J]. Chin J Parasitol Parasit Dis, 2009, 27(5): 402-411. (in Chinese)
|
|
( 汪世平, 陈秀春, 高冬梅. 我国血吸虫疫苗研究进展及应用前景[J]. 中国寄生虫学与寄生虫病杂志, 2009, 27(5): 402-411.)
|
[10] |
Molehin AJ. Schistosomiasis vaccine development: update on human clinical trials[J]. J Biomed Sci, 2020, 27(1): 28.
doi: 10.1186/s12929-020-0621-y
|
[11] |
McManus DP. Recent progress in the development of liver fluke and blood fluke vaccines[J]. Vaccines, 2020, 8(3): 553.
doi: 10.3390/vaccines8030553
|
[12] |
Torres-Rivera A, Landa A. Glutathione transferases from parasites: a biochemical view[J]. Acta Trop, 2008, 105(2): 99-112.
pmid: 17897613
|
[13] |
Capron A, Riveau G, Capron M, et al. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials[J]. Trends Parasitol, 2005, 21(3): 143-149.
pmid: 15734662
|
[14] |
Boulanger D, Warter A, Sellin B, et al. Vaccine potential of a recombinant glutathione S-transferase cloned from Schistosoma haematobium in primates experimentally infected with an homologous challenge[J]. Vaccine, 1999, 17(4): 319-326.
pmid: 9987169
|
[15] |
Riveau G, Deplanque D, Remoué F, et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis[J]. PLoS Negl Trop Dis, 2012, 6(7): e1704.
doi: 10.1371/journal.pntd.0001704
|
[16] |
Riveau G, Schacht AM, Dompnier JP, et al. Safety and efficacy of the rSh28GST urinary schistosomiasis vaccine: a phase 3 randomized, controlled trial in Senegalese children[J]. PLoS Negl Trop Dis, 2018, 12(12): e0006968.
doi: 10.1371/journal.pntd.0006968
|
[17] |
Chen B, Wen JF. Progress of research on parasitic adaptability of schistosome and its application value[J]. Chin J Schisto Control, 2014, 26(1): 84-89. (in Chinese)
|
|
( 陈兵, 文建凡. 血吸虫的寄生适应性研究及其应用价值[J]. 中国血吸虫病防治杂志, 2014, 26(1): 84-89.)
|
[18] |
Santini-Oliveira M, Coler RN, Parra J, et al. Schistosomiasis vaccine candidate Sm14/GLA-SE: phase 1 safety and immunogenicity clinical trial in healthy, male adults[J]. Vaccine, 2016, 34(4): 586-594.
doi: S0264-410X(15)01442-5
pmid: 26571311
|
[19] |
Tendler M, Almeida MS, Vilar MM, et al. Current status of the Sm14/GLA-SE schistosomiasis vaccine: overcoming barriers and paradigms towards the first anti-parasitic human(Itarian) vaccine[J]. Trop Med Infect Dis, 2018, 3(4): 121.
|
[20] |
Tran MH, Pearson MS, Bethony JM, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis[J]. Nat Med, 2006, 12(7): 835-840.
pmid: 16783371
|
[21] |
Kifle DW, Chaiyadet S, Waardenberg AJ, et al. Uptake of Schistosoma mansoni extracellular vesicles by human endothelial and monocytic cell lines and impact on vascular endothelial cell gene expression[J]. Int J Parasitol, 2020, 50(9): 685-696.
doi: 10.1016/j.ijpara.2020.05.005
|
[22] |
Keitel WA, Potter GE, Diemert D, et al. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area[J]. Vaccine, 2019, 37(43): 6500-6509.
doi: S0264-410X(19)31151-X
pmid: 31515141
|
[23] |
Siddiqui AA, Siddiqui SZ. Sm-p80-based schistosomiasis vaccine: preparation for human clinical trials[J]. Trends Parasitol, 2017, 33(3): 194-201.
doi: S1471-4922(16)30193-3
pmid: 27865740
|
[24] |
Zhang WD, Molehin AJ, Rojo JU, et al. Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy[J]. Ann N Y Acad Sci, 2018, 1425(1): 38-51.
doi: 10.1111/nyas.13942
|
[25] |
Siddiqui AJ, Molehin AJ, Zhang WD, et al. Sm-p80-based vaccine trial in baboons: efficacy when mimicking natural conditions of chronic disease, praziquantel therapy, immunization, and Schistosoma mansoni re-encounter[J]. Ann N Y Acad Sci, 2018, 1425(1): 19-37.
doi: 10.1111/nyas.13866
|
[26] |
Ahmad G, Zhang WD, Torben W, et al. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic[J]. J Infect Dis, 2011, 204(9): 1437-1449.
doi: 10.1093/infdis/jir545
pmid: 21921206
|
[27] |
Langenberg MCC, Hoogerwerf MA, Koopman JPR, et al. A controlled human Schistosoma mansoni infection model to advance novel drugs, vaccines and diagnostics[J]. Nat Med, 2020, 26(3): 326-332.
doi: 10.1038/s41591-020-0759-x
pmid: 32066978
|
[28] |
Zhang LL, Xu XD, Pan WQ. An investigation of polymorphism in the tetraspanin-2 gene of Schistosoma japonicum[J]. Int J Med Parasit Dis, 2011, 38(5): 257-260. (in Chinese)
|
|
( 张丽丽, 徐新东, 潘卫庆. 日本血吸虫被膜蛋白Sj-TSP2基因序列多态性分析[J]. 国际医学寄生虫病杂志, 2011, 38(5): 257-260.)
|
[29] |
Molehin AJ, Gray SA, Turner C, et al. Process development of sj-p80: a low-cost transmission-blocking veterinary vaccine for asiatic schistosomiasis[J]. Front Immunol, 2021, 11: 578715.
doi: 10.3389/fimmu.2020.578715
|